Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Carl G. Engelke1, Leslie A. Parsels2, Yushen Qian1, Qiang Zhang1, David Karnak1, Jordan R. Robertson1, Daria M. Tanka2, Dongping Wei1, Mary A. Davis1, Joshua D. Parsels2, Lili Zhao4, Joel K. Greenson3, Theodore S. Lawrence1, Jonathan Maybaum2, and Meredith A. Morgan1

Abstract

Purpose: The combination of radiation with chemotherapy is the most effective therapy for unresectable pancreatic cancer. To improve upon this regimen, we combined the selective Checkpoint kinase 1 (Chk1) inhibitor MK8776 with gemcitabine-based chemoradiation in preclinical pancreatic cancer models.

Experimental Design: We tested the ability of MK8776 to sensitize to gemcitabine-radiation in homologous recombination repair (HRR)–proficient and –deficient pancreatic cancer cells and assessed Rad51 focus formation. In vivo, we investigated the efficacy, tumor cell selectivity, and pharmacodynamic biomarkers of sensitization by MK8776.

Results: We found that MK8776 significantly sensitized HRR-proficient (AsPC-1, MiaPaCa-2, BxPC-3) but not -deficient (Capan-1) pancreatic cancer cells to gemcitabine-radiation and inhibited Rad51 focus formation in HRR-proficient cells. In vivo, MiaPaCa-2 xenografts were significantly sensitized to gemcitabine-radiation by MK8776 without significant weight loss or observable toxicity in the small intestine, the dose-limiting organ for chemoradiation therapy in pancreatic cancer. We also assessed pChk1 (S345), a pharmacodynamic biomarker of DNA damage in response to Chk1 inhibition in both tumor and small intestine and found that MK8776 combined with gemcitabine or gemcitabine-radiation produced a significantly greater increase in pChk1 (S345) in tumor relative to small intestine, suggesting greater DNA damage in tumor than in normal tissue. Furthermore, we demonstrated the utility of an ex vivo platform for assessment of pharmacodynamic biomarkers of Chk1 inhibition in pancreatic cancer.

Conclusions: Together, our results suggest that MK8776 selectively sensitizes HRR-proficient pancreatic cancer cells and xenografts to gemcitabine-radiation and support the clinical investigation of MK8776 in combination with gemcitabine-radiation in locally advanced pancreatic cancer.

Cancer Therapy: Preclinical

Introduction

Despite progress in the management of advanced pancreatic cancer, the prognosis for patients remains dismal. Although the use of FOLFIRINOX in the metastatic setting and concurrent gemcitabine-based chemoradiation in the locally advanced setting has produced incremental improvements in survival, more effective therapies are desperately needed (1, 2). Local disease management is an important issue in pancreatic cancer, as evidenced by the findings that 30% of patients die from local progression (3) and local control with radiation improves survival (2, 4). However, the median survival for patients with locally advanced disease remains approximately 1 year (although our recent results and those of others are more encouraging; refs. 5, 6). Thus, we sought to build upon these promising clinical results by the addition of a molecularly targeted agent to chemoradiation in pancreatic cancer.

Checkpoint kinase 1 (Chk1) is an important molecular target for sensitizing cancer cells to DNA-damaging agents. In response to DNA damage, Chk1 inhibits Cdc25 phosphatases resulting in cyclin–Cdk inhibition and cell-cycle arrest (notably, G1 arrest). In addition, Chk1 plays a role in activation of homologous recombination repair (HRR; refs. 7, 8). Thus, impairment of the DNA damage response by Chk1 inhibition renders cells more sensitive to DNA damage. Selectivity of this sensitization for tumor cells is a critical issue, and the consensus of many independent...
Translational Relevance

Chemoradiation (vs. chemotherapy alone) improves survival in locally advanced pancreatic cancer and, thus, represents the best standard platform on which to improve outcome. Chk1 inhibitors in combination with chemotherapy are now entering phase II clinical trials, and it is likely that Chk1 inhibitors in combination with chemoradiation will produce an even greater therapeutic benefit in the locally advanced disease setting. One outstanding issue in the development of Chk1 inhibitors is whether sensitization can be achieved selectively in tumors. In this study, we show the efficacy and tumor cell selectivity of sensitization to chemoradiation by Chk1 inhibition and assess pharmacodynamic biomarkers of this sensitization. The findings of this study should aid in the design of clinical trials using Chk1 inhibitors with chemoradiation in pancreatic cancer.

studies supports a model in which sensitization occurs preferentially in p53-mutant tumor cells (9–11). After DNA damage, normal cells are protected by their p53-mediated G1 checkpoint in the presence of Chk1 inhibition, whereas p53-mutant tumor cells lack this G1 checkpoint and are sensitized by G2 checkpoint abrogation in response to Chk1 inhibition. Small-molecule inhibitors of Chk1 have been an intense area of investigation in the last decade and, as a result, a number of potential clinical candidates are now under active clinical investigation, including: LY2603618, LY2606368, and MK8776 (formerly, SCH900776; refs. 12, 13). Work from our laboratory has shown that Chk1 inhibition by AZD7762 sensitizes pancreatic cancer cells and tumors to gemcitabine-radiation and that inhibition of HRR is an important underlying mechanism of this sensitization (8). Furthermore, our previous work identified pChk1 (S345) as a pharmacodynamic biomarker of Chk1 inhibition through increased ATR/ATM-mediated phosphorylation of Chk1 that occurs in response to the heighted DNA damage associated with Chk1 inhibition (14, 15). Given our underlying clinical goal of combining Chk1 inhibition with gemcitabine-radiation in pancreatic cancer, in the present study we evaluated a selective Chk1 inhibitor, MK8776, which is advancing to phase II trials, in combination with gemcitabine-radiation in preclinical models of pancreatic cancer. Although this is the first study to evaluate MK8776 in combination with radiation and chemoradiation, it has been shown to sensitize to various chemotherapies including gemcitabine and cytarabine (12, 16). Importantly, we also investigated the tumor cell selectivity of this regimen by examining the DNA damage response not only in tumors but also in normal tissues. We found that MK8776 sensitized pancreatic cancer cells to gemcitabine and gemcitabine-radiation, but only in an HRR competent setting and in association with inhibition of Rad51 focus formation. Thus, we went on to determine the effects of MK8776 in combination with gemcitabine and radiation on pancreatic tumor xenograft growth as well as on biomarkers of Chk1 inhibition in both tumor and normal tissues. Furthermore, we introduce a new platform for the ex vivo assessment of pharmacodynamic biomarkers in pancreatic cancer.

Materials and Methods

Cell culture and drug solutions

AsPC-1, MiaPaCa-2, and BxPC-3 cells were obtained from the American Type Culture Collection (ATCC). Capan-1 Neo cells were obtained from S. Powell (Memorial Sloan Kettering Cancer Center, New York, NY; ref. 17). Cells were cultured in Dulbecco’s modified Eagle medium (DMEM; MiaPaCa-2), RPMI (AsPC-1, BxPC-3), or IMDM (Capan-1) supplemented with 10% FBS, 2 mmol/L glutamine, and antibiotics. MK8776 was obtained from Merck and prepared as 10 mmol/L stock solutions in DMSO for in vitro studies. For in vivo use, 5 mg/mL MK8776 was dissolved in 5% dextrose monohydrate (pH 6.5; Sigma) and administered by intraperitoneal injection. Gemcitabine (Eli Lilly) was dissolved in PBS or saline for in vitro and in vivo use, respectively.

Clonogenic survival

Exponentially growing cells were treated with drugs/radiation and then replated at cloning densities. Cells were grown for 9 to 14 days and then fixed and stained with methanol-acetic acid and crystal violet, respectively, and scored for colonies of 50 cells or more. Drug cytotoxicity was calculated as the ratio of surviving drug-treated cells relative to untreated control cells. Radiation survival data from drug-treated cells were corrected for drug cytotoxicity. Cell survival curves were fitted using the linear-quadratic equation, and the mean inactivation dose calculated according to the method of Fertil and colleagues (18). The radiation enhancement ratio was calculated as the ratio of the mean inactivation dose under control conditions divided by the mean inactivation dose under drug-treated conditions.

Immunofluorescence

Cells cultured and treated on cover slips were fixed and processed as previously described except with a mouse monoclonal Rad51 antibody (GeneFex; ref. 19). Samples were imaged with an Olympus IX71 Fluoview confocal microscope (Olympus America) with an ×60 oil objective. For quantitation of Rad51 foci, at least 100 cells from each of three independent experiments were visually scored for each condition.

Immunohistochemistry

Tissues were fixed in 10% neutral buffered formalin for 24 hours, then embedded in paraffin, and sectioned at 5 μm. Sections were dehydrated to buffer and pretreated with citrate buffer, pH 6.0, for 10 minutes. After peroxidase and nonspecific blocking, sections were stained with pChk1 (S345) antibody (Cell Signaling Technology) at a dilution
of 1:200 overnight at 4°C, followed the next day with the
Envision+ Rabbit detection kit (room temperature) on a
DAKO Autostainer (DAKO North America). Chromogen
was applied for 5 minutes and sections were counterstained
with hematoxylin. Immunohistochemistry was conducted
by the University of Michigan Cancer Center Research
Histology and Immunoperoxidase Lab. Specimens were
evaluated microscopically with an ×20 objective on an
Olympus IX71 microscope (Olympus America) with a
Nikon DS-Fi1 camera and NIS-Elements software (Nikon).
Samples were scored blindly by counting the number of
positive and negative nuclei in a representative field.
Between 300 and 800 cells were scored for each sample.

Immunoblotting
Pulverized tissues were lysed and immunoblotted as
previously described (20). Proteins were detected with
antibodies recognizing pChk1 (S345), pChk1 (S296),
GAPDH (Cell Signaling Technology), and total Chk1 (Santa
Cruz Biotechnology).

Irradiation
Irradiations were carried out using a Philips RT250 (Kim-
tron Medical) at a dose rate of approximately 2 Gy/min in
the University of Michigan Comprehensive Cancer Center
Experimental Irradiation Core. Dosimetry was carried out
using an ionization chamber connected to an electrometer
system that is directly traceable to a National Institute of
Standards and Technology calibration. For tumor irradi-
ation, animals were anesthetized with isoflurane and posi-
tioned such that the apex of each flank tumor was at the
center of a 2.4 cm aperture in the secondary collimator, with
the rest of the mouse shielded from radiation. For simul-
taneous irradiation of flank tumors and small intestines,
mice were placed in a prone position and a 2 × 8 cm²
aperture in the secondary collimator was used.

Tumor growth studies
Animals were handled according to a protocol approved
by the University of Michigan Committee for Use and Care
of animals. MiaPaCa-2 cells (5 × 10⁶) were suspended in
a 1:1 mixture of 10% FBS/DMEM:Matrigel (BD Biosciences)
and injected subcutaneously, bilaterally into the flanks of 3-
week-old, female, athymic nude mice. Treatment was
initiated when the average tumor volume reached 100 mm³.
Tumor size was measured 2 times per week; tumor volume
was calculated according to the equation:

\[ TV = \pi / 6 \times (ab^2) \]

where a and b are the longer and shorter dimensions
of the tumor, respectively. Measurements were made until
the tumor volume increased by approximately a factor of 4.

Tumor slicing
Tumors of approximately 300 mm³ were collected asep-
tically and embedded in 3% low-melting-point agarose.
Two hundred micrometer slices were prepared with a Leica
VT 1200S microtome with vibrating blade (Leica Micro-
systems) while submerged in oxygenated, ice-cold Krebs
buffer, according to the previously described methodology
(21). Slices were incubated in 12-well dishes containing
DMEM (ATCC) supplemented with 2 mmol/L glutamine,
penicillin, streptomycin, antibiotic–antimycotic (Gibco),
and 20 mmol/L HEPES (pH 7.4) in a carbogen (95% O₂, 5%
CO₂) purged chamber inside a 37°C, humidified, 5% CO₂
incubator for up to 30 hours, after which they were pro-
cessed for biochemical or immunohistochemical analysis
using the same methods as for intact tumors.

Statistical analysis
For tumor growth experiments, the time required for
radioresistance was determined for each xenograft
by identifying the earliest day on which it was at least twice
as large as on the first day of treatment. The Kaplan–Meier
method was used to analyze the doubling times. Log-rank
test (PROC LIFETEST in SAS) was used to compare the
doubling times between any two treatment groups. In
addition, the Bayesian hierarchical changepoint (BHC)
model was used to compare tumor regression rates, regres-
ion periods, and regrowth rates between any two treatment
groups. Biomarker data were analyzed using a mixed effect
model (PROC MIXED in SAS), with a random effect model-
ing correlation between normal and tumor cells in the same
animal. A Student t test or one-way ANOVA with a Tukey
post hoc test was used for other analyses.

Results
To begin to determine the ability of MK8776 to sensitize
to chemoradiation in pancreatic cancer cells, we first
assessed sensitization to gemcitabine by MK8776 in a panel
of p53-mutant pancreatic cancer cell lines. Cells were treated
with IC₅₀ concentrations of gemcitabine followed by
MK8776 at increasing concentrations. We found, in the
order of magnitude of sensitization, that MiaPaCa-2, BxPC-
3, and AsPC-1 cells were sensitized to gemcitabine
MK8776 (Fig. 1), whereas Capan-1 cells were only mini-
mally sensitized. Sensitization occurred at concentrations
of MK8776 which produced minimal single-agent toxicity
(Supplementary Fig. S1).

We next assessed whether MK8776 would sensitize
pancreatic cancer cells to gemcitabine-based chemoradia-
tion. Cells were treated with a previously optimized
schedule of gemcitabine followed by MK8776 and radi-
ation (8, 14). We used nontoxic concentrations of gem-
 citabine that produced little radiosensitization alone
and minimally toxic concentrations of MK8776, which
were sufficient to abrogate the G₂ checkpoint (Supple-
mentary Fig. S2) and inhibit Chk1 autophosphorylation
(16). Treatment of AsPC-1, MiaPaCa-2, and BxPC-3 cells
with MK8776 did not produce significant radiosensitiza-
tion, although there was a trend toward marginal radio-
sensitization under these minimally toxic MK8776 con-
ditions (Fig. 2; Supplementary Table S1). Importantly,
MK8776 did significantly sensitize AsPC-1, MiaPaCa-2, and
BxPC-3 cells, but not Capan-1 cells, to gemcitabine-
radiation. Consistent with this observation, MK8776
treatment caused persistent DNA damage, reflected by
γH2AX expression in response to gemcitabine-radiation
in MiaPaCa-2 but not Capan-1 cells (Supplementary Fig. S3). Given that Capan-1 cells harbor a BRCA2 mutation rendering them HRR incompetent (17) while no BRCA2 mutation is present in the other pancreatic cancer cell lines, these findings suggest that HRR may play a role in sensitization by MK8776.

To specifically assess HRR we measured Rad51 focus formation in response to gemcitabine, MK8776, and radiation. Rad51, a DNA recombinase that promotes template strand invasion, is a key intermediary in HRR and forms foci at sites of HRR-mediated DNA double-strand break repair (22). In MiaPaCa-2 cells, Rad51 focus formation was induced in response to gemcitabine and/or radiation treatment and, as anticipated, MK8776 inhibited Rad51 focus formation in response to gemcitabine/radiation, although the magnitude of this effect appeared greatest in the presence of gemcitabine (Fig. 3A and B). In BxPC-3 cells, the inhibitory effect of MK8776 on Rad51 foci was only evident in response to gemcitabine plus radiation (Fig. 3C and D). This result is consistent with the chemoradiosensitization by MK8776 observed in these cells (Fig. 2). Together, these results show that the ability of MK8776 to inhibit Rad51

![Figure 1. Chemosensitization by MK8776 in pancreatic cancer cells. Exponentially growing pancreatic cancer cells were treated with an IC_{50} concentration of gemcitabine (AsPC-1, 500 nmol/L; MiaPaCa-2 and BxPC-3, 250 nmol/L; Capan-1, 50 nmol/L) for 2 hours (t, 0–2 hours) followed by increasing concentrations of MK8776 (t, 24–48 hours). At the end of drug exposure, cells were processed for clonogenic survival. The surviving fraction was normalized to the MK8776 alone plating efficiency for each respective concentration. B, the sensitization factor was calculated as (surviving fraction, Gem only)/(surviving fraction, Gem + MK8776). The MK8776 concentration used to calculate the sensitization factor was 500 nmol/L except in AsPC-1, which was 250 nmol/L. Data are the mean ± SE of n, 3–4 independent experiments.](image1)

![Figure 2. Sensitization to chemoradiation by MK8776 in pancreatic cancer cells. Pancreatic cancer cell lines were treated with minimally cytotoxic concentrations of gemcitabine (AsPC-1, 100 nmol/L; MiaPaCa-2 and BxPC-3, 50 nmol/L; Capan-1, 25 nmol/L) for 2 hours (t, 0–2 hours) followed by MK8776 (500 nmol/L except in AsPC-1, 250 nmol/L, t, 23–48 hours), and radiation (0–8 Gy, t, 24 hours). At the end of treatment, cells were processed for clonogenic survival. Data are from a single representative experiment (plots) or are the mean radiation enhancement ratio ± SE for n, 3–4 independent experiments (in parenthesis). Statistical significance (P < 0.05) versus control (†) or Gem (‡) is indicated. Cytotoxicity is summarized in Supplementary Table S1.](image2)
focus formation after gemcitabine-radiation is associated with sensitization.

We then aimed to determine the efficacy of MK8776 on pancreatic tumor growth in response to gemcitabine and radiation. Mice bearing MiaPaCa-2 xenografts were treated with MK8776 in combination with gemcitabine and radiation for 2 weeks, and tumor growth was monitored during and after therapy. We found that treatment with modest doses of gemcitabine or MK8776 alone produced minimal effect on tumor growth (Fig. 4). Although the combination of gemcitabine and MK8776 appeared to inhibit tumor growth more than either single agent, this effect did not reach significance. As expected, radiation treatment prolonged the time required for tumor volume doubling.

Figure 4. MK8776 sensitizes pancreatic tumor xenografts to chemoradiation. Athymic nude mice bearing bilateral, subcutaneous MiaPaCa-2 xenografts were treated with Gem (120 mg/kg, Mon, t, 0 hour), MK8776 (50 mg/kg, Mon–Fri, t, 2 hours), and radiation (1 Gy/fraction, Mon–Fri, t, 3 hours) for 2 cycles. Data are the mean normalized tumor volume ± SE of \( n = 12–18 \) tumors per condition (A) or are the median tumor volume doubling time (symbols) with upper and lower limits (lines) for \( n = 12–18 \) tumors per condition (B). Statistical significance determined by the log-rank test versus control (†) or Gem RT (‡) is indicated.
Likewise, the combination of modest doses of gemcitabine or MK8776 with radiation prolonged the time required for tumor volume doubling relative to untreated tumors ($P = 0.0001$ or $P = 0.0195$, respectively), but this effect was not significant relative to radiation treatment. Importantly, the combination of these same modest doses of MK8776 with gemcitabine-radiation significantly delayed the tumor volume doubling time relative to gemcitabine-radiation treatment ($P = 0.0087$) without a significant effect on weight loss (Supplementary Fig. S4). In addition, using the BHC statistical model (23), we noted that, during treatment with the combination of gemcitabine, MK8776, and radiation, tumors did not grow for an average of 10 days (90% confidence interval: 5–14 days), whereas tumor growth occurred throughout treatment with gemcitabine-radiation. These results support the conclusion that MK8776 sensitizes pancreatic tumors to chemoradiation.

To assess the Chk1-mediated DNA damage response in tumors, mice bearing MiaPaCa-2 xenografts were acutely treated with MK8776, gemcitabine, and radiation. The levels of both ATR/ATM-mediated phosphorylation (S345) as well as autophosphorylation (S296) of Chk1 in tumors were then measured. We found that pChk1 (S345) levels increased in response to either gemcitabine or MK8776, while the combination of the two produced an even greater level of pChk1 (S345; Fig. 5A). In tumors treated with radiation, there was a slight increase in pChk1 (S345) that was maximal in response to the combination of MK8776 + gemcitabine + radiation. This increase in pChk1 (S345) in response to Chk1 inhibition has been previously established and is thought to occur as a result of increased DNA damage in response to Chk1 inhibition as well as a feedback loop with protein phosphatase 2A (14, 24). Indeed, we found that induction of pChk1 (S345) was in general agreement with

![Figure 5.](https://example.com/figure5.png)
γ-H2AX expression in response to MK8776, gemcitabine, and radiation. Consistent with Chk1 inhibition by MK8776, Chk1 autophosphorylation (S296) was inhibited under all conditions in which MK8776 was present. The effects of treatment on pChk1 (S345) were largely reproduced by immunohistochemistry, where strong nuclear pChk1 (S345) staining was observed in response to MK8776 + gemcitabine + radiation (Fig. 5B and D; Supplementary Fig. S5).

Clinically, the combination of gemcitabine with radiation for pancreatic cancer is limited by toxicity to the small intestine. We hypothesized that DNA damage measured by phosphorylation of Chk1 (S345) would be increased by MK8776 in combination with gemcitabine-radiation in tumor cells, but not in normal cells, as normal cells should be protected by an intact p53-mediated G1 checkpoint, whereas p53-mutant tumor cells should not. Small intestines were harvested from treated, tumor-bearing mice and assessed by immunohistochemistry for pChk1 (S345) protein levels. MK8776 treatment alone increased pChk1 (S345) levels in the intestinal crypt cells but not in the intestinal villar cells, a result likely related to the role Chk1 plays during DNA synthesis in rapidly dividing cells (Fig. 5C and D; refs. 12, 25). However, this early increase in pChk1 (S345) in the intestinal crypt cells in response to MK8776 was not associated with any observable long-term toxicity (Supplementary Fig. S4). More importantly, the addition of MK8776 to gemcitabine or gemcitabine-radiation produced a significantly greater effect on pChk1 (S345) in tumor relative to small intestine. To specifically test whether MK8776 sensitized small intestine to gemcitabine-radiation, we conducted a jejunal crypt assay, as we have done previously (26). We found, with the exception of positive control-treated mice, that none of the treatments, including MK8776 combined with gemcitabine-radiation, produced any observable loss of crypt viability (Supplementary Fig. S6). This result is consistent with a minimal effect of MK8776 in combination with gemcitabine-radiation on weight loss (Supplementary Fig. S4). Collectively, these results show that Chk1 inhibition produces more DNA damage and, thus, greater sensitization in response to gemcitabine/radiation in tumors than in normal tissues.

The need for pharmacodynamic biomarkers of response in pancreatic cancer and the complexity associated with pre- and posttreatment biopsies in patients, we initiated an ex vivo biomarker system with the long-term goal of being able to assess pharmacodynamic biomarkers in patient tumors from a single biopsy. To this end, 200 μm thick slices of MiaPaCa-2 xenografts were treated ex vivo with MK8776, gemcitabine, and radiation. Similar to the results obtained following in vivo treatment (Fig. 5A and B), pChk1 (S345) was induced in response to MK8776 and, to a greater extent, in combination with gemcitabine/radiation (Fig. 6). Consistent with phosphorylation of Chk1 at S345 triggering ubiquitin-mediated degradation of Chk1 (19, 27), we observed a decrease in total Chk1 protein in response to treatment with gemcitabine and MK8776 (with or without radiation). Induction of pChk1 (S296) was inhibited by MK8776. Immunohistochemistry revealed that the induction of pChk1 (S345) mirrored that seen in the in vivo-treated xenografts and also showed that the structural integrity of the tumors was maintained using this tissue...
slicing approach (Fig. 6B and C; Supplementary Fig. S7). Taken together, these results show that this ex vivo biomarker approach can recapitulate an in vivo pharmacodynamic response and warrant further studies to determine whether this platform has potential usefulness in the clinic.

Discussion

In this study, we have found that inhibition of Chk1 by MK8776 sensitizes pancreatic cancers to gemcitabine-radiation through mechanisms involving inhibition of HRR. Importantly, our animal studies suggest that sensitization of tumor cells to gemcitabine-radiation by Chk1 inhibition occurs selectively in tumor cells relative to small intestines. In addition, we show that pChk1 (S345) is a useful pharmacodynamic biomarker of MK8776 sensitization in tumor cells and introduce an ex vivo biomarker platform for the assessment of pancreatic tumor specimens. These results support clinical investigation of MK8776 with gemcitabine-radiation in patients with locally advanced pancreatic cancer.

A number of Chk1 inhibitors have been developed preclinically as sensitizers with the intent of combining them with standard chemotherapy/radiation in the clinic. In our previous work, we investigated the Chk1/Chk2 inhibitor AZD7762 in combination with chemoradiation in pancreatic cancer. Unlike AZD7762, which has equal affinity for Chk1 and Chk2 (28), MK8776 is approximately 500 times more selective for Chk1 than Chk2 (12). We noted differences between AZD7762 and MK8776 in terms of their "pure" radiosensitizing properties. Both in vitro and in vivo, AZD7762 was a very effective radiosensitizer, whereas single-agent MK8776 produced less radiosensitization (8, 10). Although our previous studies suggested Chk1 was the key target of AZD7762 for modulating radiosensitization (8), it is still intriguing to consider the possibility that the ability of AZD7762 to radiosensitize is, in part, attributable to its activity against Chk2 or some other target. Others have found that inhibition of Chk2 radiosensitizes cancer cells (29). In terms of chemosensitization, MK8776 and AZD7762 are similar (14). Most importantly, both AZD7762 and MK8776 produced significant sensitization to gemcitabine-radiation, which is crucial in the context of developing a new treatment for locally advanced pancreatic cancer.

Tumor cell selectivity is a critical issue in the development of any new cancer treatment. Specifically with regard to Chk1 inhibitors, there are at least two factors to consider: tumor cell selectivity of sensitization and tumor cell selectivity of Chk1 inhibitor monotherapy. Sensitization by Chk1 inhibition is thought to occur in a p53 mutation-dependent manner, whereby normal cells are protected by their p53-mediated G1 checkpoint whereas p53-mutant tumor cells are not. There is substantial literature to support this model (10, 11), although it is likely that other genetic aberrations contribute to this selectivity (30). With respect to the effects of Chk1 inhibitors as monotherapy, the emerging evidence that Chk1 inhibition causes DNA damage in replicating cells (31–33) has led to the hypothesis that the deleterious effects of Chk1 inhibition should preferentially occur in tumor cells based on their higher fraction of cycling cells and elevated levels of endogenous DNA damage due to genetic aberrations relative to normal cells (25). Because small intestine is the dose-limiting toxicity for chemoradiation therapy of pancreatic cancer, we investigated the effects of Chk1 inhibition on sensitization of the small intestine to chemoradiation. To our knowledge, this is the first study to examine the sensitizing effects of a small-molecule Chk1 inhibitor on a normal tissue. Consistent with the role of Chk1 in replicating cells, we found pS345 Chk1 was induced in both tumor and small intestines following treatment with MK8776 alone. Notably, the pChk1 (S345) induction in the small intestines was restricted only to the replicating crypt cells. Although we have noted that pS345 Chk1 is a surrogate marker for DNA damage in tumors (14), the meaning of this marker in crypt cells is less clear, because there was no evidence of intestinal toxicity (weight loss or loss of crypt viability). More importantly, in the small intestines, the addition of gemcitabine/radiation to MK8776 did not produce any additional pChk1 (S345) or intestinal crypt toxicity, suggesting that no sensitization occurred in the small intestines. In tumors, however, the addition of gemcitabine/radiation to MK8776 produced a significant increase in pChk1 (S345) relative to MK8776 alone and was associated with the greatest tumor growth delay. Taken together, these results suggest that Chk1 inhibition by MK8776 selectively sensitizes tumor, but not small intestine, to gemcitabine/radiation.

An interesting finding of this study is that MK8776 did not sensitize to chemoradiation in HRR-deficient pancreatic cancer cells. Our previous work suggested that HRR inhibition was a mechanism of radiosensitization by Chk1 inhibitors, but left unclear the relative contributions of HRR inhibition versus G2 checkpoint abrogation to sensitization. The finding that Capan-1 cells, which are rendered HRR-incompetent by a BRCA2 mutation, are not sensitized to gemcitabine/radiation by MK8776 (despite G2 checkpoint abrogation by MK8776; data not shown) suggests that HRR inhibition is a major mechanism of sensitization. Consistent with previous reports, the effects of MK8776 on Rad51 focus formation (Fig. 3) support the hypothesis that HRR is a major target of Chk1 inhibition. Given that BRCA1/2 mutations are quite rare in pancreatic cancer (34), these results are favorable in the context of the broader applicability of Chk1 inhibitors as sensitizers in pancreatic cancers.

The development of a molecularly targeted agent in pancreatic cancer should involve the confirmation that both the target and the subsequent downstream signaling are inhibited. In the absence of a primary resection, patient pancreatic tumor specimens are generally limited to a one-time fine-needle aspirate or a small core needle biopsy. Although this may be adequate for assessing "static" biomarkers (such p53 or K-Ras mutation status), it is insufficient for the assessment of pharmacodynamic responses, which require pre- and posttreatment comparison. Furthermore, while p53 mutation status is a useful biomarker to some extent, it does not capture the degree of sensitization as, even in p53-mutant
cells, Chk1 inhibition produces a wide range of sensitization (Fig. 1). Thus, the development of pharmacodynamic biomarkers of Chk1 inhibition is important and has the potential to be predictive of the degree of tumor sensitization. To begin to develop a system which would permit pharmacodynamic assessment of a biomarker from a one-time biopsy in pancreatic cancer, we have integrated methodology which uses thinly sliced fresh tissue (21) into an \textit{ex vivo} treatment platform. It will be important in future studies to determine if \textit{ex vivo} biomarker analyses are feasible on patient pancreatic tumor biopsies and whether they are predictive of therapeutic efficacy (35).

Our preclinical finding that MK8776 improves the efficacy of gemicitabine-radiation in pancreatic cancer xenografts provides further support for the clinical development of Chk1 inhibitors in combination with chemoradiation. In order to best use Chk1 inhibitors such as MK8776 with chemoradiation, however, a few outstanding issues need to be addressed. Although \(p53\) is one of several candidate biomarkers for tumor sensitization following Chk1 inhibition, the relationship of \(p53\) mutation status or that of other candidate biomarkers, such as \(K-Ras\), \(BRCA1/2\), or \(DPC4\), with clinical outcome remains to be established. Similarly, while pChk1 (S345) appears to be a reliable biomarker for Chk1 inhibition and DNA damage, it is still unclear whether changes in pChk1 (S345), or other dynamic biomarkers such as \(\gamma\)-H2AX or Rad51, correlate with clinical response. Furthermore, with the clinical development of agents that target different molecules in the Chk1 response network, such as Wee1, it is plausible that different subsets of tumors may respond more to Chk1 inhibitors compared with another targeted agent, and \textit{vice versa}. Thus, it will be important to compare these agents to Chk1 inhibitors in terms of their efficacy and tumor cell selectivity, as well as to identify biomarkers which predict the superiority of one agent over the others. Finally, it is of interest to begin to understand the mechanisms of resistance that may be incurred in response to Chk1 inhibition in tumor cells.

\section*{Disclosure of Potential Conflicts of Interest}
No potential conflicts of interest were disclosed.

\section*{Authors' Contributions}

\textbf{Conception and design:} C. Engelke, L. Parsels, T. Lawrence, J. Maybaum, M.A. Morgan  
\textbf{Development of methodology:} C. Engelke, J. Robertson, T. Lawrence, J. Maybaum, M.A. Morgan  
\textbf{Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):} C. Engelke, L. Parsels, Y. Qian, Q. Zhang, D. Karnak, J. Robertson, D. Tanska, M. Davis, J. Parsels, M.A. Morgan  
\textbf{Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):} C. Engelke, L. Parsels, Y. Qian, D. Karnak, D. Wei, M. Davis, J. Parsels, L. Zhao, J.K. Greenson, T. Lawrence, J. Maybaum, M.A. Morgan  
\textbf{Writing, review, and/or revision of the manuscript (i.e., reporting or organizing data, constructing databases):} Y. Qian, M. Davis  
\textbf{Study supervision:} T. Lawrence, J. Maybaum, M.A. Morgan

\section*{Grant Support}
This work was funded by NIH Grants R01CA163895 (to M.A. Morgan), R01CA138723 (to T. Lawrence and J. Maybaum), P50CA130810 (to T. Lawrence and J. Maybaum), and Cancer Center Core Grant P30 CA046592 (to T. Lawrence), and an Alfred B. Taubman Scholarship (to T. Lawrence).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked \textit{advertisement} in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received December 12, 2012; revised June 7, 2013; accepted June 17, 2013; published OnlineFirst June 26, 2013.

\section*{References}

Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

Carl G. Engelke, Leslie A. Parsels, Yushen Qian, et al.

Clin Cancer Res Published OnlineFirst June 26, 2013.

Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-12-3748

Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2013/06/28/1078-0432.CCR-12-3748.DC1

Sign up to receive free email-alerts related to this article or journal.

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.